Evens Ronald, Kaitin Kenneth
Ronald Evens (
Kenneth Kaitin is a professor at and director of the Tufts Center for the Study of Drug Development, Tufts University School of Medicine.
Health Aff (Millwood). 2015 Feb;34(2):210-9. doi: 10.1377/hlthaff.2014.1023.
For more than three decades the field of biotechnology has had an extraordinary impact on science, health care, law, the regulatory environment, and business. During this time more than 260 novel biotechnology products were approved for over 230 indications. Global sales of these products exceeded $175 billion in 2013 and have helped sustain a vibrant life sciences sector that includes more than 4,600 biotech companies worldwide. In this article we examine the evolution of biotechnology during the past three decades and the profound impact that it has had on health care through four interrelated and interdependent tracks: innovations in science, government activity, business development, and patient care. The future impact of biotechnology is promising, as long as the public and private sectors continue to foster policies and provide funds that lead to scientific breakthroughs; governments continue to offer incentives for private-sector biotech innovation; industry develops business models for cost-effective research and development; and all stakeholders establish policies to ensure that the therapeutic advances that mitigate or cure medical conditions that currently have inadequate or no available therapies are accessible to the public at a reasonable cost.
三十多年来，生物技术领域对科学、医疗保健、法律、监管环境和商业产生了非凡影响。在此期间，超过260种新型生物技术产品被批准用于230多种适应症。这些产品在2013年的全球销售额超过1750亿美元，并助力维持了一个充满活力的生命科学领域，全球范围内有超过4600家生物技术公司。在本文中，我们通过四个相互关联且相互依存的方面来审视过去三十年生物技术的发展历程及其对医疗保健产生的深远影响：科学创新、政府活动、商业发展和患者护理。只要公共部门和私营部门继续推行相关政策并提供资金以推动科学突破；政府继续为私营部门的生物技术创新提供激励措施；行业开发出具有成本效益的研发商业模式；并且所有利益相关者制定政策，确保公众能够以合理成本获得那些可缓解或治愈目前治疗方法不足或尚无可用治疗方法的医疗状况的治疗进展，那么生物技术的未来影响前景广阔。
